These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 21913869

  • 1. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab.
    Baumgartner A, Stich O, Rauer S.
    Int J Neurosci; 2012 Jan; 122(1):35-9. PubMed ID: 21913869
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
    Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C, Guiziou C, Kassiotis P, Lallement F, Laplaud D, Diraison P, Rouhart F, Sartori E, Wardi R, Wiertlewski S, Edan G.
    J Neurol Sci; 2011 Sep 15; 308(1-2):98-102. PubMed ID: 21665227
    [Abstract] [Full Text] [Related]

  • 3. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
    Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J.
    Mult Scler; 2012 Jun 15; 18(6):899-901. PubMed ID: 22183929
    [Abstract] [Full Text] [Related]

  • 4. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 15; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 May 17; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 7. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 17; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 8. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
    [Abstract] [Full Text] [Related]

  • 9. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Mar 02; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 10. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C.
    J Neurol Sci; 2012 Dec 15; 323(1-2):104-12. PubMed ID: 23006974
    [Abstract] [Full Text] [Related]

  • 11. MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis.
    Grimaldi LM, Prosperini L, Vitello G, Borriello G, Fubelli F, Pozzilli C.
    Mult Scler; 2012 Sep 15; 18(9):1337-9. PubMed ID: 22389413
    [Abstract] [Full Text] [Related]

  • 12. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
    O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N.
    Neurology; 2011 May 31; 76(22):1858-65. PubMed ID: 21543733
    [Abstract] [Full Text] [Related]

  • 13. Lethal multiple sclerosis relapse after natalizumab withdrawal.
    Rigau V, Mania A, Béfort P, Carlander B, Jonquet O, Lassmann H, Camu W, Thouvenot E.
    Neurology; 2012 Nov 27; 79(22):2214-6. PubMed ID: 23100404
    [No Abstract] [Full Text] [Related]

  • 14. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F, Calabrese M, Seppi D, Puthenparampil M, Perini P, Gallo P.
    Mult Scler; 2012 Dec 27; 18(12):1760-7. PubMed ID: 22570359
    [Abstract] [Full Text] [Related]

  • 15. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.
    JAMA Neurol; 2014 Aug 27; 71(8):954-60. PubMed ID: 24977406
    [Abstract] [Full Text] [Related]

  • 16. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
    Rinaldi F, Perini P, Calabrese M, Rinaldi L, Gallo P.
    Mult Scler; 2009 Nov 27; 15(11):1359-62. PubMed ID: 19812116
    [Abstract] [Full Text] [Related]

  • 17. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P, Szabo K, Hornberger E, Griebe M, Hennerici MG, Kieseier BC, Gass A.
    J Neuroimaging; 2014 Nov 27; 24(4):425-8. PubMed ID: 23323645
    [Abstract] [Full Text] [Related]

  • 18. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy.
    Berger JR.
    Mult Scler; 2008 Jun 27; 14(5):708-10. PubMed ID: 18566035
    [Abstract] [Full Text] [Related]

  • 19. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D.
    N Engl J Med; 2005 Jul 28; 353(4):375-81. PubMed ID: 15947078
    [Abstract] [Full Text] [Related]

  • 20. Deaths and disability from natalizumab are no longer tolerable: Yes.
    Duquette P.
    Mult Scler; 2012 Aug 28; 18(8):1068-9. PubMed ID: 22807470
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.